# OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026

- Source: PR Newswire M&A
- Published: 2026-11-06T14:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/oncoc4-reports-encouraging-phase-12-data-for-cesalatamig-monotherapy-in-previously-treated-non-small-cell-lung-cancer-at-sitc-2026-302931874.html
- Canonical: https://groundlevelnews.com/story/oncoc4-reports-encouraging-phase-1-2-data-for-cesalatamig-monotherapy--864d41/

— 33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refractory NSCLC — — Preliminary efficacy and safety results support further development of cesalatamig monotherapy — ROCKVILLE, Md., Nov. 6,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._